Physician profile
Jonathan Philip Igo
NPI 1215476643
$16,871.07
in general payments reported to CMS, 2019-2025
21 companies · $4,509 in 2025
The $4,509 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7.30 · 2022: $647 · 2023: $2,603 · 2024: $9,105 · 2025: $4,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,546 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,000 · Travel and Lodging: $1,251 · Education: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,545.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,000.00 |
| Travel and Lodging | $1,250.57 |
| Education | $420.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $8,597.76 | 2023-2025 | Ycanth |
| Abbvie INC. | $1,330.09 | 2022-2025 | |
| Genzyme Corporation | $849.98 | 2022-2025 | |
| Janssen Biotech, INC. | $789.77 | 2021-2025 | Tremfya |
| Incyte Corporation | $741.47 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $691.95 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $531.28 | 2022-2025 | Adbry |
| Lilly USA, LLC | $527.44 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $436.80 | 2023-2025 | Dupixent, Libtayo |
| Ucb, INC. | $434.36 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $385.42 | 2022-2025 | |
| Galderma Laboratories, L.P. | $327.03 | 2024-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $274.21 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $239.35 | 2022-2025 | Winlevi |
| Dermavant Sciences, INC. | $211.25 | 2023-2024 | Vtama |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $174.83 | 2022-2025 | |
| Amgen INC. | $123.72 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $109.77 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $49.62 | 2023-2024 | Tremfya |
| Almirall LLC | $31.66 | 2023 | Klisyri |
| Boston Scientific Corporation | $13.31 | 2023 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Igo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.